Gilead Sciences, Inc. (GILD)
- Sector
- Health Care
- Industry
- Biotechnology
- Last price
- $153.54
- As of
Kresmion compiles this page from GILD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
GILEAD SCIENCES, INC. (GILD): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
See the full GILD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GILD on one page. Preview it with sample data, then open it live with a free account.
Preview the GILD dossierActive signals for GILD
- highCONSENSUS_BUY
6 tracked funds increased GILD this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +235% to GILD (2026Q2)
- highCONSENSUS_BUY
4 tracked funds increased GILD this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +169% to GILD (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +11494% to GILD (2026Q2)
FREE, NO ACCOUNT
Every signal on GILD, as it fires
You are seeing 5 of 91 signals recorded on GILD since 2026-05-02.
The five above landed across 2 days. The other 86 were recorded on 23 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GILD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 375558103 · 2026Q2 | $439.7M | 0.05% | , |
| D. E. Shaw & Co., Inc.CUSIP 375558103 · 2026Q2 | $289.9M | 0.14% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 375558103 · 2026Q2 | $280.1M | 0.39% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 375558103 · 2026Q2 | $184.3M | 0.07% | , |
| Point72 Asset Management, L.P.CUSIP 375558103 · 2026Q2 | $181.6M | 0.20% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 375558103 · 2026Q2 | $51.7M | 0.04% | , |
| Bridgewater Associates, LPCUSIP 375558103 · 2026Q2 | $36.7M | 0.15% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GILD
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
GILD against its peers
GILD's operating margin of 34.0% ranks in the 74th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | GILD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 29.4B USD | 3.0B USD | 88 | 20 |
| Operating margin | 34.0% | 23.1% | 74 | 20 |
| Net margin | 28.9% | 13.1% | 70 | 21 |
| Return on equity | 37.5% | 11.2% | 88 | 20 |
| P / E | 22.6x | 29.1x | 38 | 11 |
| 1 year | 29.6% | 29.8% | 48 | 19 |
Peers (23): AMGN, VRTX, MRNA, REGN, ABBV, NTRA, ARGX, RVMD, ONC, BIIB, ALNY, ROIV, RPRX, BNTX, UTHR, INCY, GMAB, INSM, ASND, EXEL, NBIX, SMMT, BBIO. Left out: CSLLY (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (GILD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GILD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GILD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.